In collaboration with doctors from University of California, San Diego (UCSD) School of Medicine, Bennu plans to initiate a Phase IIa clinical study of delayed release cysteamine (DR Cysteamine) in non-alcoholic steatohepatitis (NASH) patients in 2008.
Ted Daley, president of Bennu, said: “We are delighted to extend our relationship with UCSD. Additional rights to cysteamine in NASH complement our license to DR Cysteamine for cystinosis and neurodegenerative diseases.”